Trial Outcomes & Findings for BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors (NCT NCT04455620)

NCT ID: NCT04455620

Last Updated: 2025-07-02

Results Overview

• Recruitment status: TERMINATED
• Study phase: PHASE1/PHASE2
• Target enrollment: 49 participants
• Primary outcome timeframe: From first dose of IMP up to 21 days (Cycle 1).
• Results posted on: 2025-07-02

Participant Flow

The study was conducted at centers experienced in first-in-human studies in two countries, i.e., the US and Spain.

A total of 49 participants were enrolled in this study and all participants received at least one dose of the IMP.

Participant milestones

Measure	BNT151 0.4 ug/kg Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 2.0 ug/kg Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 4.0 ug/kg Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 8.0 ug/kg Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 2.0 + 4.0 ug/kg Participants from Part 1 treated with BNT151 monotherapy with pre-conditioning. Treatment started with a pre-conditioning dose (a lower dose of 2 μg/kg) on Day 1 of the pre-conditioning cycle (cycle of 7 days). The participants then received the intended dose of 4 μg/kg at the discretion of the safety review committee (SRC) on Day 1 of every Q3W treatment cycle.
Overall Study STARTED	1	8	24	2	14
Overall Study COMPLETED	0	0	0	0	0
Overall Study NOT COMPLETED	1	8	24	2	14

Reasons for withdrawal

Measure	BNT151 0.4 ug/kg Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 2.0 ug/kg Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 4.0 ug/kg Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 8.0 ug/kg Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 2.0 + 4.0 ug/kg Participants from Part 1 treated with BNT151 monotherapy with pre-conditioning. Treatment started with a pre-conditioning dose (a lower dose of 2 μg/kg) on Day 1 of the pre-conditioning cycle (cycle of 7 days). The participants then received the intended dose of 4 μg/kg at the discretion of the safety review committee (SRC) on Day 1 of every Q3W treatment cycle.
Overall Study Withdrawal by Subject	0	0	2	0	1
Overall Study Lost to Follow-up	0	0	1	1	0
Overall Study Death	1	6	20	1	7
Overall Study Study Termination	0	2	1	0	6

Baseline Characteristics

BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors

Baseline characteristics by cohort

Measure	BNT151 0.4 ug/kg n=1 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 2.0 ug/kg n=8 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 4.0 ug/kg n=24 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 8.0 ug/kg n=2 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 2.0 + 4.0 ug/kg n=14 Participants Participants from Part 1 treated with BNT151 monotherapy with pre-conditioning. Treatment started with a pre-conditioning dose (a lower dose of 2 μg/kg) on Day 1 of the pre-conditioning cycle (cycle of 7 days). The participants then received the intended dose of 4 μg/kg at the discretion of the SRC on Day 1 of every Q3W treatment cycle.	Total n=49 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants
Age, Categorical Between 18 and 65 years	0 Participants n=5 Participants	7 Participants n=7 Participants	13 Participants n=5 Participants	1 Participants n=4 Participants	6 Participants n=21 Participants	27 Participants n=10 Participants
Age, Categorical >=65 years	1 Participants n=5 Participants	1 Participants n=7 Participants	11 Participants n=5 Participants	1 Participants n=4 Participants	8 Participants n=21 Participants	22 Participants n=10 Participants
Sex: Female, Male Female	0 Participants n=5 Participants	4 Participants n=7 Participants	9 Participants n=5 Participants	1 Participants n=4 Participants	8 Participants n=21 Participants	22 Participants n=10 Participants
Sex: Female, Male Male	1 Participants n=5 Participants	4 Participants n=7 Participants	15 Participants n=5 Participants	1 Participants n=4 Participants	6 Participants n=21 Participants	27 Participants n=10 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants	1 Participants n=7 Participants	5 Participants n=5 Participants	0 Participants n=4 Participants	3 Participants n=21 Participants	9 Participants n=10 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	1 Participants n=5 Participants	5 Participants n=7 Participants	15 Participants n=5 Participants	1 Participants n=4 Participants	6 Participants n=21 Participants	28 Participants n=10 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	2 Participants n=7 Participants	4 Participants n=5 Participants	1 Participants n=4 Participants	5 Participants n=21 Participants	12 Participants n=10 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=10 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	2 Participants n=10 Participants
Race (NIH/OMB) White	1 Participants n=5 Participants	7 Participants n=7 Participants	18 Participants n=5 Participants	2 Participants n=4 Participants	7 Participants n=21 Participants	35 Participants n=10 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	5 Participants n=5 Participants	0 Participants n=4 Participants	6 Participants n=21 Participants	11 Participants n=10 Participants
Body mass index (BMI) category <18 kg/m^2	0 participants n=5 Participants	0 participants n=7 Participants	0 participants n=5 Participants	0 participants n=4 Participants	1 participants n=21 Participants	1 participants n=10 Participants
Body mass index (BMI) category ≥18 to <25 kg/m^2	0 participants n=5 Participants	2 participants n=7 Participants	8 participants n=5 Participants	0 participants n=4 Participants	6 participants n=21 Participants	16 participants n=10 Participants
Body mass index (BMI) category ≥25 to <30 kg/m^2	0 participants n=5 Participants	2 participants n=7 Participants	8 participants n=5 Participants	1 participants n=4 Participants	6 participants n=21 Participants	17 participants n=10 Participants
Body mass index (BMI) category ≥30 kg/m^2	1 participants n=5 Participants	4 participants n=7 Participants	8 participants n=5 Participants	1 participants n=4 Participants	1 participants n=21 Participants	15 participants n=10 Participants

PRIMARY outcome

Timeframe: From first dose of IMP up to 21 days (Cycle 1).

Population: DLT evaluable set, including all participants from the safety set who were enrolled in dose-escalation cohorts and either experienced a DLT during the DLT evaluation period (Cycle 1) or completed the DLT evaluation period. Participants who did not experience any DLT during the DLT observation period were considered to be evaluable if they have been observed for minimum 21 days following the first dose and were considered to have sufficient safety data to conclude that a DLT did not occur.

Outcome measures

Measure	BNT151 0.4 ug/kg n=1 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 2.0 ug/kg n=8 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 4.0 ug/kg n=24 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 8.0 ug/kg n=2 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 2.0 + 4.0 ug/kg n=14 Participants Participants from Part 1 treated with BNT151 monotherapy with pre-conditioning. Treatment started with a pre-conditioning dose (a lower dose of 2 μg/kg) on Day 1 of the pre-conditioning cycle (cycle of 7 days). The participants then received the intended dose of 4 μg/kg at the discretion of the SRC on Day 1 of every Q3W treatment cycle.
Number of Participants With Dose Limiting Toxicities (DLTs) During the DLT Evaluation Period in Part 1	0 participants	0 participants	0 participants	2 participants	0 participants

PRIMARY outcome

Timeframe: From first dose of IMP through study completion, a maximum of 30 months.

Population: Safety set, i.e., all participants who received IMP (i.e., at least one dose of BNT151).

A TEAE was defined as any adverse event (AE) with an onset date on or after the first administration of IMP (if the AE was absent before the first administration of IMP) or worsened after the first administration of IMP (if the AE was present before the first administration of IMP). AEs with an onset date more than 60 days after the last administration of IMP were considered as treatment emergent only if assessed as related to IMP by the investigator.

The intensity of an TEAE was graded according to the NCI CTCAE version 5.0. Grade 3=Severe, Grade 4=Life threatening, Grade 5=Death.

Outcome measures

Measure	BNT151 0.4 ug/kg n=1 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 2.0 ug/kg n=8 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 4.0 ug/kg n=24 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 8.0 ug/kg n=2 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 2.0 + 4.0 ug/kg n=14 Participants Participants from Part 1 treated with BNT151 monotherapy with pre-conditioning. Treatment started with a pre-conditioning dose (a lower dose of 2 μg/kg) on Day 1 of the pre-conditioning cycle (cycle of 7 days). The participants then received the intended dose of 4 μg/kg at the discretion of the SRC on Day 1 of every Q3W treatment cycle.
Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) Including Grade ≥3, Serious, Fatal TEAE by Relationship TEAE	1 Participants	8 Participants	24 Participants	2 Participants	14 Participants
Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) Including Grade ≥3, Serious, Fatal TEAE by Relationship TEAE related to BNT151	0 Participants	7 Participants	23 Participants	2 Participants	11 Participants
Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) Including Grade ≥3, Serious, Fatal TEAE by Relationship Grade ≥3 TEAE	1 Participants	3 Participants	14 Participants	2 Participants	5 Participants
Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) Including Grade ≥3, Serious, Fatal TEAE by Relationship Grade ≥3 TEAE related to BNT151	0 Participants	3 Participants	8 Participants	1 Participants	2 Participants
Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) Including Grade ≥3, Serious, Fatal TEAE by Relationship TEAE related to study procedure	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants
Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) Including Grade ≥3, Serious, Fatal TEAE by Relationship Serious TEAE	0 Participants	3 Participants	9 Participants	2 Participants	4 Participants
Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) Including Grade ≥3, Serious, Fatal TEAE by Relationship Serious TEAE related to BNT151	0 Participants	1 Participants	5 Participants	2 Participants	0 Participants
Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) Including Grade ≥3, Serious, Fatal TEAE by Relationship Serious TEAE leading to death	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) Including Grade ≥3, Serious, Fatal TEAE by Relationship Serious TEAE related to BNT151 leading to death	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: From first dose of IMP through treatment completion, a maximum of 24 months.

Population: Safety set, i.e., all participants who received IMP (i.e., at least one dose of BNT151).

A TEAE was defined as any AE with an onset date on or after the first administration of IMP (if the AE was absent before the first administration of IMP) or worsened after the first administration of IMP (if the AE was present before the first administration of IMP). AEs with an onset date more than 60 days after the last administration of IMP were considered as treatment emergent only if assessed as related to IMP by the investigator.

Outcome measures

Measure	BNT151 0.4 ug/kg n=1 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 2.0 ug/kg n=8 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 4.0 ug/kg n=24 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 8.0 ug/kg n=2 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 2.0 + 4.0 ug/kg n=14 Participants Participants from Part 1 treated with BNT151 monotherapy with pre-conditioning. Treatment started with a pre-conditioning dose (a lower dose of 2 μg/kg) on Day 1 of the pre-conditioning cycle (cycle of 7 days). The participants then received the intended dose of 4 μg/kg at the discretion of the SRC on Day 1 of every Q3W treatment cycle.
Number of Paticipants With at Least One TEAE Leading to Dose Reduction, Dose Interruption, and Treatment Discontinuation of BNT151 TEAE leading to dose reduction	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Paticipants With at Least One TEAE Leading to Dose Reduction, Dose Interruption, and Treatment Discontinuation of BNT151 TEAE leading to dose interruption	0 Participants	0 Participants	4 Participants	0 Participants	2 Participants
Number of Paticipants With at Least One TEAE Leading to Dose Reduction, Dose Interruption, and Treatment Discontinuation of BNT151 TEAE leading to permanent treatment discontinuation of BNT151	0 Participants	0 Participants	2 Participants	1 Participants	0 Participants

SECONDARY outcome

Timeframe: Through study completion, a maximum of 30 months.

Population: Treated set, i.e., defined as all participants who received IMP (i.e., at least one dose of BNT151).

ORR was defined as the proportion of participants in whom a complete response (CR) or partial response (PR) (per RECIST version 1.1) was observed as best overall response.

Confirmed ORR was defined as the proportion of participants in whom a CR or PR (per RECIST version 1.1) was observed as best overall response and has been confirmed with a subsequent assessment of objective response at least 4 weeks apart.

Outcome measures

Measure	BNT151 0.4 ug/kg n=1 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 2.0 ug/kg n=8 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 4.0 ug/kg n=24 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 8.0 ug/kg n=2 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 2.0 + 4.0 ug/kg n=14 Participants Participants from Part 1 treated with BNT151 monotherapy with pre-conditioning. Treatment started with a pre-conditioning dose (a lower dose of 2 μg/kg) on Day 1 of the pre-conditioning cycle (cycle of 7 days). The participants then received the intended dose of 4 μg/kg at the discretion of the SRC on Day 1 of every Q3W treatment cycle.
Objective Response Rate (ORR) ORR	0 percentage of participants Interval 0.0 to 97.5	0 percentage of participants Interval 0.0 to 36.9	4.2 percentage of participants Interval 0.1 to 21.1	0 percentage of participants Interval 0.0 to 84.2	7.1 percentage of participants Interval 0.2 to 33.9
Objective Response Rate (ORR) Confirmed ORR	0 percentage of participants Interval 0.0 to 97.5	0 percentage of participants Interval 0.0 to 36.9	4.2 percentage of participants Interval 0.1 to 21.1	0 percentage of participants Interval 0.0 to 84.2	7.1 percentage of participants Interval 0.2 to 33.9

SECONDARY outcome

Timeframe: Through study completion, a maximum of 30 months.

Population: Treated set, i.e., defined as all participants who received IMP (i.e., at least one dose of BNT151).

DCR was defined as the proportion of participants in whom a CR or PR or stable disease (SD) (per RECIST version 1.1, SD assessed at least 6 weeks after first dose) was observed as best overall response.

Outcome measures

Measure	BNT151 0.4 ug/kg n=1 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 2.0 ug/kg n=8 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 4.0 ug/kg n=24 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 8.0 ug/kg n=2 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 2.0 + 4.0 ug/kg n=14 Participants Participants from Part 1 treated with BNT151 monotherapy with pre-conditioning. Treatment started with a pre-conditioning dose (a lower dose of 2 μg/kg) on Day 1 of the pre-conditioning cycle (cycle of 7 days). The participants then received the intended dose of 4 μg/kg at the discretion of the SRC on Day 1 of every Q3W treatment cycle.
Disease Control Rate (DCR)	0 percentage of partients Interval 0.0 to 97.5	25 percentage of partients Interval 3.2 to 65.1	25 percentage of partients Interval 9.8 to 46.7	0 percentage of partients Interval 0.0 to 84.2	42.9 percentage of partients Interval 17.7 to 71.1

SECONDARY outcome

Timeframe: Through study completion, a maximum of 30 months.

Population: Treated set, i.e., defined as all participants who received IMP (i.e., at least one dose of BNT151).

DOR was defined as the time from first objective response (CR or PR per RECIST version 1.1) to first occurrence of objective tumor progression (progressive disease per RECIST version 1.1) or death from any cause, whichever occurred first.

Reporting groups with zero participants with confirmed objective response are not included.

Outcome measures

Measure	BNT151 0.4 ug/kg n=1 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 2.0 ug/kg n=1 Participants Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 4.0 ug/kg Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 8.0 ug/kg Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 2.0 + 4.0 ug/kg Participants from Part 1 treated with BNT151 monotherapy with pre-conditioning. Treatment started with a pre-conditioning dose (a lower dose of 2 μg/kg) on Day 1 of the pre-conditioning cycle (cycle of 7 days). The participants then received the intended dose of 4 μg/kg at the discretion of the SRC on Day 1 of every Q3W treatment cycle.
Duration of Response (DOR)	6.5 months Confidence interval values value could not be estimated.	NA months Value could not be calculated because participant was censored as per SAP defined censoring rules (i.e., no progression / lost to follow up).	—	—	—

Adverse Events

BNT151 0.4 ug/kg

Serious events: 0 serious events

Other events: 1 other events

Deaths: 1 deaths

BNT151 2.0 ug/kg

Serious events: 3 serious events

Other events: 8 other events

Deaths: 6 deaths

BNT151 4.0 ug/kg

Serious events: 9 serious events

Other events: 24 other events

Deaths: 20 deaths

BNT151 8.0 ug/kg

Serious events: 2 serious events

Other events: 2 other events

Deaths: 1 deaths

BNT151 2.0 + 4.0 ug/kg

Serious events: 4 serious events

Other events: 14 other events

Deaths: 7 deaths

Serious adverse events

Measure	BNT151 0.4 ug/kg n=1 participants at risk Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 2.0 ug/kg n=8 participants at risk Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 4.0 ug/kg n=24 participants at risk Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 8.0 ug/kg n=2 participants at risk Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 2.0 + 4.0 ug/kg n=14 participants at risk Participants from Part 1 treated with BNT151 monotherapy with pre-conditioning. Treatment started with a pre-conditioning dose (a lower dose of 2 μg/kg) on Day 1 of the pre-conditioning cycle (cycle of 7 days). The participants then received the intended dose of 4 μg/kg at the discretion of the SRC on Day 1 of every Q3W treatment cycle.
Blood and lymphatic system disorders Anaemia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Gastrointestinal disorders Abdominal pain	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	8.3% 2/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Gastrointestinal disorders Ascites	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 1/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Gastrointestinal disorders Intestinal obstruction	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Gastrointestinal disorders Large intestinal obstruction	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
General disorders Influenza like illness	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	50.0% 1/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
General disorders Non-cardiac chest pain	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
General disorders Pyrexia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	16.7% 4/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Hepatobiliary disorders Hyperbilirubinaemia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	50.0% 1/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Immune system disorders Cytokine release syndrome	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	50.0% 1/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Infections and infestations Device related infection	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 1/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Infections and infestations Pneumonia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Infections and infestations Pyelonephritis	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	8.3% 2/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Injury, poisoning and procedural complications Vascular access complication	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Nervous system disorders Headache	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 1/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Vascular disorders Hypotension	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 1/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.

Other adverse events

Measure	BNT151 0.4 ug/kg n=1 participants at risk Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 2.0 ug/kg n=8 participants at risk Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 4.0 ug/kg n=24 participants at risk Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 8.0 ug/kg n=2 participants at risk Participants from Part 1 treated with BNT151 monotherapy. BNT151 was administered intravenously on Day 1 of each 3-week treatment cycle (Q3W; 21 days).	BNT151 2.0 + 4.0 ug/kg n=14 participants at risk Participants from Part 1 treated with BNT151 monotherapy with pre-conditioning. Treatment started with a pre-conditioning dose (a lower dose of 2 μg/kg) on Day 1 of the pre-conditioning cycle (cycle of 7 days). The participants then received the intended dose of 4 μg/kg at the discretion of the SRC on Day 1 of every Q3W treatment cycle.
Gastrointestinal disorders Diarrhoea	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 1/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	20.8% 5/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	50.0% 1/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Gastrointestinal disorders Dyspepsia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Gastrointestinal disorders Dysphagia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 1/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Gastrointestinal disorders Enterovesical fistula	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Gastrointestinal disorders Nausea	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	25.0% 2/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	29.2% 7/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Gastrointestinal disorders Rectal haemorrhage	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	50.0% 1/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Gastrointestinal disorders Stomatitis	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Gastrointestinal disorders Vomiting	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	16.7% 4/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
General disorders Asthenia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 1/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	21.4% 3/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
General disorders Chest pain	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
General disorders Chills	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 1/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 3/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	21.4% 3/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
General disorders Fatigue	100.0% 1/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	25.0% 2/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 3/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	35.7% 5/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
General disorders Oedema peripheral	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 1/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	50.0% 1/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
General disorders Pain	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
General disorders Peripheral swelling	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
General disorders Pyrexia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 1/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	25.0% 6/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	14.3% 2/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Hepatobiliary disorders Hyperbilirubinaemia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	50.0% 1/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Hepatobiliary disorders Hypertransaminasaemia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	50.0% 1/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Immune system disorders Cytokine release syndrome	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	8.3% 2/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Infections and infestations Bronchitis	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Infections and infestations COVID-19	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 3/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Infections and infestations Respiratory tract infection	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Infections and infestations Respiratory tract infection viral	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Infections and infestations Urinary tract infection	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 3/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Injury, poisoning and procedural complications Infusion related reaction	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	25.0% 2/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	37.5% 9/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	71.4% 10/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Injury, poisoning and procedural complications Skin laceration	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Injury, poisoning and procedural complications Skin wound	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Investigations Alanine aminotransferase increased	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	25.0% 2/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Investigations Aspartate aminotransferase increased	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	37.5% 3/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Investigations Blood alkaline phosphatase increased	100.0% 1/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 1/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 3/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Investigations Blood creatinine increased	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	16.7% 4/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	14.3% 2/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Investigations Lymphocyte count decreased	100.0% 1/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	50.0% 4/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	50.0% 12/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Investigations Neutrophil count decreased	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Investigations Platelet count decreased	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	50.0% 1/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Investigations Red blood cell count decreased	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Investigations Weight decreased	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Investigations White blood cell count decreased	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 3/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Investigations White blood cell count increased	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	20.8% 5/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Metabolism and nutrition disorders Dehydration	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 1/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 1/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	8.3% 2/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	25.0% 2/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 3/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	14.3% 2/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	8.3% 2/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	8.3% 2/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Musculoskeletal and connective tissue disorders Tendonitis	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Cancer pain	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour haemorrhage	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Nervous system disorders Dizziness	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Nervous system disorders Dysaesthesia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Nervous system disorders Headache	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	25.0% 2/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Nervous system disorders Syncope	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 1/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Nervous system disorders Transient ischaemic attack	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Psychiatric disorders Anxiety	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	14.3% 2/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Psychiatric disorders Depression	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Psychiatric disorders Insomnia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Renal and urinary disorders Choluria	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	50.0% 1/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Renal and urinary disorders Haematuria	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	8.3% 2/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Renal and urinary disorders Hydronephrosis	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	8.3% 2/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Renal and urinary disorders Micturition urgency	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	8.3% 2/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Renal and urinary disorders Nephrolithiasis	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Renal and urinary disorders Renal failure	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	8.3% 2/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Renal and urinary disorders Urinary retention	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	25.0% 2/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	8.3% 2/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	14.3% 2/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Respiratory, thoracic and mediastinal disorders Dysphonia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 1/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 1/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	8.3% 2/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Respiratory, thoracic and mediastinal disorders Nasal discomfort	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 1/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Respiratory, thoracic and mediastinal disorders Tachypnoea	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 1/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Skin and subcutaneous tissue disorders Rash	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	8.3% 2/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Vascular disorders Deep vein thrombosis	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Vascular disorders Embolism venous	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Vascular disorders Flushing	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Vascular disorders Hypertension	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Vascular disorders Hypotension	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	14.3% 2/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Blood and lymphatic system disorders Anaemia	100.0% 1/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	25.0% 2/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	45.8% 11/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	21.4% 3/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Blood and lymphatic system disorders Leukopenia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Blood and lymphatic system disorders Neutropenia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	50.0% 1/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Cardiac disorders Atrial fibrillation	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	50.0% 1/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Cardiac disorders Sinus tachycardia	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 3/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Endocrine disorders Hypothyroidism	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Eye disorders Dry eye	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Eye disorders Keratitis	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Eye disorders Visual impairment	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	4.2% 1/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Gastrointestinal disorders Abdominal distension	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	8.3% 2/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Gastrointestinal disorders Abdominal pain	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 1/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	8.3% 2/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	14.3% 2/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Gastrointestinal disorders Anal haemorrhage	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Gastrointestinal disorders Ascites	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	8.3% 2/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	50.0% 1/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.
Gastrointestinal disorders Constipation	0.00% 0/1 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	12.5% 1/8 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	20.8% 5/24 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	0.00% 0/2 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.	7.1% 1/14 • Deaths and serious AEs: All events from the signing of the study-specific ICF until early study termination, i.e., up to 31 months. Other AEs: All TEAEs, i.e., AEs reported from the start of study drug treatment until until early study termination, i.e., up to 30 months. Other AEs: All TEAEs, i.e., any AE with an onset date on or after the first dose of BNT151 (if the AE was absent before the first dose) or worsened after the first dose of BNT151 (if the AE was present before the first dose). AEs with an onset date \>60 days after the last dose of BNT151 were included only if assessed as related to BNT151 by the investigator. If a participant experienced more than one event in a category, the participant is counted only once in that category.

Additional Information

BioNTech clinical trials patient information

BioNTech SE

Phone: +49 6131 9084

Email: patients@biontech.de

Results disclosure agreements

• Principal investigator is a sponsor employee Principal Investigators respectively study sites shall not publish or refer to in writing or orally, in whole or in part, any data, information or materials generated from the study and the services, without the prior written consent of the sponsor.
• Publication restrictions are in place

Restriction type: OTHER